BioSpace News Archive

Annexon, Inc., a clinical stage biopharmaceutical company developing novel therapies for patients with classical complement-mediated disorders of the body, brain and eye, announced that patient dosing has begun in its Phase 2 ARCHER study of its anti-C1q therapy, ANX007, to treat Geographic Atrophy.

Cerecor Inc., a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases, announced the appointment of Schond L. Greenway as Chief Financial Officer, effective March 1, 2021.

Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company is pleased to announce that it has appointed Dr. Christopher Bryan PhD as Vice President, Research & Operations and Dr. Ahmad Khalil MD, PhD as the Company’s Chief Medical Officer.

BrainsWay Ltd., a global leader in the advanced noninvasive treatment of brain disorders, announced the closing of its previously announced underwritten public offering of 5,315,300 American Depositary Shares, upsized to include 693,300 ADSs sold pursuant to the underwriters’ exercise in full of their option to purchase additional ADSs, at a price to the public of $8.50 per ADS.

Arvinas, Inc., a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update.

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the fourth quarter and year ended December 31, 2020.

At a virtual meeting with the investment community, Viatris Inc. will outline how the company expects to lead as a new kind of healthcare company with a unique and differentiated business model, high-quality operational platform and clear focus on ensuring its sustainability priorities and financial commitments are met.

Bio-Techne Corporation announced that Humana has awarded a contract effective April 1, 2021 to its Exosome Diagnostics laboratory, covering the ExoDx™ Prostate test for men.

Centene Corporation announced four executive leadership appointments to support the company’s continued growth and innovation.

EchoInsight® Strain imaging Standardizes Analysis and Interpretation, while Improving Diagnostic Assessment and Optimizing Care Through Better Patient Monitoring